Neumora Therapeutics, Inc. (NASDAQ: NMRA) is a hot penny stock with an Outperform rating. Mizuho analyst raised the price target to $5 from $4 after introducing NMRA-861 for schizophrenia treatment. The drug is estimated to generate $1.2 billion in sales by 2037. Neumora focuses on precision medicine for CNS diseases.

While NMRA shows investment potential, AI stocks may offer more upside. An undervalued AI stock could benefit from Trump-era tariffs and onshoring trends. For more insights, check out the best short-term AI stock report. Neumora Therapeutics, Inc. is a clinical-stage biotech company pioneering neuroscience and data science integration for brain disease treatments.

Read more at Yahoo Finance: Mizuho Lifts PT on Neumora Therapeutics (NMRA) to $5 from $4, Keeps Outperform Rating